|
Schirdewan博士的引述的參考文獻:
1 G5 X8 Z) N+ [' G; [" ?
: f% d! b8 B( n3 UCamm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. # [2 U& i$ n7 c h/ G) w N# k
U5 y! D& s7 X; { vDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008 $ [# k. e7 x% d( n0 k
* x* {3 d! E% g' i
Ricci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. ) Y1 h0 _" M4 k6 z" @& a8 H
: |4 T9 z. q7 O1 ?. W/ M
關於BIOTRONIK SE & Co. KG
. l/ i9 W3 v9 p# [: |2 X/ ]& U- E+ Z8 W) C
BIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|